{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}],"title":"Relapse post HCT"},{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"}],"title":"Did not relapse post HCT"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"To compare which of the two, intensive chemotherapy versus hypomethylating agent-based therapy, have a factor of relapse post hematopoietic cell transplantation (HCT).","groups":[{"description":"Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine (AZC): Given IV or SC\n\nDecitabine: Given IV or SC\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm A (Decitabine or Azacitidine)"},{"description":"Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only.\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG001","title":"Arm B (Induction-like Chemotherapy Regimen)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only participants who received a HCT that relapse were assessed for this outcome.","reportingStatus":"POSTED","timeFrame":"Up to 18 months","title":"Number of Patients Who Relapse Post-transplant","type":"SECONDARY","unitOfMeasure":"Participants"}